Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Carotid B-Mode Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Mixed Hyperlipidemia

Trial Profile

Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Carotid B-Mode Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Mixed Hyperlipidemia

Discontinued
Phase of Trial: Phase III

Latest Information Update: 16 Feb 2012

At a glance

  • Drugs Torcetrapib/atorvastatin (Primary) ; Atorvastatin
  • Indications Atherosclerosis
  • Focus Biomarker; Registrational; Therapeutic Use
  • Acronyms RADIANCE-2
  • Sponsors Pfizer
  • Most Recent Events

    • 16 Feb 2012 Actual patient number changed from 752 to 755 as reported by ClinicalTrials.gov.
    • 16 Feb 2012 Planned end date (Dec 2006) added as reported by ClinicalTrials.gov.
    • 26 Mar 2007 Results data have been presented.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top